Amantadine-d6

Amantadine-d6

• CAS Number: 1219805-53-4
• UNSPSC Description: Amantadine-d6 is the deuterium labeled Amantadine[1]. Amantadine (1-Adamantanamine) is an orally avtive and potent antiviral agent with activity against influenza A viruses. Amantadine inhibits several ion channels such as NMDA and M2, and also inhibits Coronavirus ion channels. Amantadine also has anti-orthopoxvirus and anticancer activity. Amantadine can be used for Parkinson's disease, postoperative cognitive dysfunction (POCD) and COVID-19 research[2][3][4][5][6][7].
• Target Antigen: Apoptosis; Bcl-2 Family; CDK; Influenza Virus; Orthopoxvirus; SARS-CoV
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Apoptosis;Cell Cycle/DNA Damage
• Applications: COVID-19-anti-virus
• Field of Research: Cancer
• Purity: 98.10
• Solubility: 10 mM in DMSO
• Smiles: NC12C([2H])(C3CC(C2([2H])[2H])CC(C1([2H])[2H])C3)[2H]
• Molecular Weight: 157.29
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.|[2]Suzuki H, et al. Emergence of amantadine-resistant influenza A viruses: epidemiological study. J Infect Chemother. 2003;9(3):195-200.|[3]Hubsher G, et al. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 201278(14):1096-1099.|[4]Donald F Smee, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan57(1-2):41-52. |[5]Fink K, et al. Amantadine Inhibits SARS-CoV-2 In Vitro. Viruses. 2021 Mar 2413(4):539. |[6]Zhang J, et al. Amantadine alleviates postoperative cognitive dysfunction possibly by increasing glial cell line-derived neurotrophic factor in rats. Anesthesiology. 2014 Oct121(4):773-85.|[7]Lan Z, et al. Amantadine inhibits cellular proliferation and induces the apoptosis of hepatocellular cancer cells in vitro. Int J Mol Med. 201536(3):904-910.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported